Alzheimer Europe’s October 2020 newsletter brings you the latest news on developments in the dementia field, across Europe and beyond.

Summaries of a few of our top stories appear below.

Our monthly newsletter reaches around 11,000 people and we are always happy to receive feedback, or suggestions regarding news items to share in future issues.


Click here to download full newsletter

1 October: Sirpa Pietikainen MEP submits written question on dementia

European Alzheimer’s Alliance Chairperson and member of the Alzheimer Europe Board, Sirpa Pietikainen MEP (EPP, Finland), has submitted a written question to the European Commission asking about the place of dementia in the future priorities of the EU.





5 October: Alzheimer Europe AGM elects new Board

Alzheimer Europe’s Annual General Meeting (AGM) was held online, on 5 October 2020. Chaired by Iva Holmerová, the meeting was attended by representatives of 28 out of 35 full member associations and 2 provisional member associations.Delegates with full voting rights elected a new Alzheimer Europe Board for the term 2020-2022.

20 October: Alzheimer Europe holds its first ever virtual Annual Conference #30AEC

The 30th Alzheimer Europe Conference (#30AEC) “Dementia in a changing world” was held online from 20-22 October 2020. Almost 800 participants, from 42 countries, attended the conference, which boasted 260 speakers and 100 poster presentations, sharing their research, projects and experiences in an atmosphere of collaboration and solidarity, against the backdrop of the global COVID-19 pandemic.

23 October: European Working Group of People with Dementia begins new term

The European Working Group of People with Dementia (EWGPWD) began its fifth two-year term of office with an online meeting on 23 October 2020. During this meeting, the group welcomed six new members.


30 October: EMA accepts to review Biogen's Marketing Authorisation Application for aducanumabeview bz EMA

This month, Biogen disclosed that it had submitted a European Medicines Agency (EMA) Marketing Authorisation Application (MAA) for aducanumab, a monoclonal β-amyloid antibody that has been evaluated in several Phase 2 and 3 clinical trials on mild Alzheimer’s disease and mild cognitive impairment (MCI). The EMA had accepted the MAA for review, following a standard timetable.